Bollard Group’s MacroGenics MGNX Stock Holding History

Bollard Group’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,474	Closed	-$22K	–	352
2022 Q1	$22K	Hold	2,474	–	–	﹤0.01%	384
2021 Q4	$40K	Hold	2,474	–	–	﹤0.01%	364
2021 Q3	$52K	Hold	2,474	–	–	﹤0.01%	345
2021 Q2	$66K	Hold	2,474	–	–	﹤0.01%	328
2021 Q1	$79K	Hold	2,474	–	–	﹤0.01%	302
2020 Q4	$57K	Hold	2,474	–	–	﹤0.01%	326
2020 Q3	$62K	Hold	2,474	–	–	﹤0.01%	304
2020 Q2	$69K	Buy	+2,474	New	+$43K	﹤0.01%	300

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bollard Group's MGNX Position: Q2 2022 in Review

Bollard Group sold out of MacroGenics (MGNX) in Q2 2022, closing a stake of 2,474 shares — an estimated $22K sold.

Bollard Group first reported a position in MGNX in Q2 2020 and held it in 8 quarters. The position peaked at $79K in Q1 2021. 133 funds tracked by Wall St. Rank hold MGNX as of Q2 2022.

Bollard Group reported no remaining MacroGenics position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 2,474 MacroGenics shares in Q2 2022, an estimated $22K.
Bollard Group first reported a position in MacroGenics in Q2 2020 and held it in 8 quarters.
Bollard Group's MacroGenics position peaked at $79K in Q1 2021.
133 funds tracked by Wall St. Rank held MacroGenics as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.